China’s National Medical Products Administration (NMPA) has approved GSK plc’s Exdensur (depemokimab) as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. The approval was based on two late‑stage trials showing modest but statistically significant reductions in nasal polyp size and nasal obstruction symptoms over one year when Exdensur was adde...